TY - JOUR
T1 - Gene transfer of a hybrid interleukin-1β gene to B16 mouse melanoma recruits leucocyte subsets and reduces tumour growth in vivo
AU - Björkdahl, Olle
AU - Wingren, Anette Gjörloff
AU - Hedlund, Gunnar
AU - Ohlsson, Lennart
AU - Dohlsten, Mikael
N1 - Funding Information:
AcknowledgementsmWe thank Eva Gynnstam for her skilful technical assistance. Financial support was provided by the Swedish Cancer Society and the LEO Research Foundation.
PY - 1997/7
Y1 - 1997/7
N2 - Interleukin(IL)-1 differs from most other cytokines in its lack of a signal sequence. This results in intracellular retention of the immature proform. The release of IL-1 has been shown to be restricted predominantly to activated monocytes and macrophages and to be associated with apoptosis of the producer cell. These features have limited the investigation of IL-1 in early immune responses, in order to study the biological effects of local IL- 1β release during an antitumour immune response, we used B16 mouse melanoma cells transduced with mature human IL-1β cDNA constructs. To obtain a released form of human IL-1β (ssIL-1β), the signal sequence from the related IL-1 receptor antagonist was ligated to the cDNA that encoded the mature form of IL-1β. When cells of the poorly immunogenic B16 melanoma cell line were transduced with IL-1β by retroviral infection, high levels of the protein were detected intracellularly, whereas cells transduced with IL-1β containing the signal sequence secreted most of their protein. The in vitro growth of the melanoma cells was unaffected by the IL-1β or ssIL-1β gene transfer. In contrast, the in vivo subcutaneous tumour growth of the ssIL- 1β-transduced B16 cells in syngeneic C57BL/6 mice was significantly reduced compared with the IL-1β and the mock-transduced controls. Immunohistochemical analysis revealed the infiltration of macrophages to be strong in B16/ssIL-1β, moderate in B16/IL-1β and minimal in control tumours. Furthermore, a moderate infiltration of CD4+ cells and of scattered dendritic cells was detected in B16/ssIL-1β tumours whereas very few or no CD4+ cells and dendritic cells were seen in the B16/IL-1β or control tumours. Following in vivo growth, all the tumours upregulated ICAM-1 on their cell surfaces. However, the percentage of ICAM-1-expressing cells was two- to fourfold higher in B16/ssIL-1β tumours compared to the control. The data suggest that IL-1β acts in vivo, either directly or indirectly, as a chemotactic factor for monocytes, T helper cells and dendritic cells. This supports IL-1β having a regulatory effect on tumour growth when locally released in the tumour area.
AB - Interleukin(IL)-1 differs from most other cytokines in its lack of a signal sequence. This results in intracellular retention of the immature proform. The release of IL-1 has been shown to be restricted predominantly to activated monocytes and macrophages and to be associated with apoptosis of the producer cell. These features have limited the investigation of IL-1 in early immune responses, in order to study the biological effects of local IL- 1β release during an antitumour immune response, we used B16 mouse melanoma cells transduced with mature human IL-1β cDNA constructs. To obtain a released form of human IL-1β (ssIL-1β), the signal sequence from the related IL-1 receptor antagonist was ligated to the cDNA that encoded the mature form of IL-1β. When cells of the poorly immunogenic B16 melanoma cell line were transduced with IL-1β by retroviral infection, high levels of the protein were detected intracellularly, whereas cells transduced with IL-1β containing the signal sequence secreted most of their protein. The in vitro growth of the melanoma cells was unaffected by the IL-1β or ssIL-1β gene transfer. In contrast, the in vivo subcutaneous tumour growth of the ssIL- 1β-transduced B16 cells in syngeneic C57BL/6 mice was significantly reduced compared with the IL-1β and the mock-transduced controls. Immunohistochemical analysis revealed the infiltration of macrophages to be strong in B16/ssIL-1β, moderate in B16/IL-1β and minimal in control tumours. Furthermore, a moderate infiltration of CD4+ cells and of scattered dendritic cells was detected in B16/ssIL-1β tumours whereas very few or no CD4+ cells and dendritic cells were seen in the B16/IL-1β or control tumours. Following in vivo growth, all the tumours upregulated ICAM-1 on their cell surfaces. However, the percentage of ICAM-1-expressing cells was two- to fourfold higher in B16/ssIL-1β tumours compared to the control. The data suggest that IL-1β acts in vivo, either directly or indirectly, as a chemotactic factor for monocytes, T helper cells and dendritic cells. This supports IL-1β having a regulatory effect on tumour growth when locally released in the tumour area.
KW - IL-1β release
KW - Signal sequence
KW - Tumour growth inhibition
U2 - 10.1007/s002620050383
DO - 10.1007/s002620050383
M3 - Article
C2 - 9247562
AN - SCOPUS:0030748450
SN - 0340-7004
VL - 44
SP - 273
EP - 281
JO - Cancer Immunology Immunotherapy
JF - Cancer Immunology Immunotherapy
IS - 5
ER -